The role of CD133 in cancer: a concise review

PM Glumac, AM LeBeau - Clinical and translational medicine, 2018 - Springer
Despite the abundant ongoing research efforts, cancer remains one of the most challenging
diseases to treat globally. Due to the heterogenous nature of cancer, one of the major …

The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?

V Plaks, N Kong, Z Werb - Cell stem cell, 2015 - cell.com
Cancer stem cells (CSCs) are tumor cells that have the principal properties of self-renewal,
clonal tumor initiation capacity, and clonal long-term repopulation potential. CSCs reside in …

CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges

P Grosse‐Gehling, CA Fargeas, C Dittfeld… - The Journal of …, 2013 - Wiley Online Library
The cancer stem cell (CSC) hypothesis, despite the limitations of the currently available
models and assays, has ushered in a new era of excitement in cancer research. The …

Therapeutic strategies targeting cancer stem cells

GJ Yoshida, H Saya - Cancer science, 2016 - Wiley Online Library
Cancer stem cells (CSC s) are undifferentiated cancer cells with a high tumorigenic activity,
the ability to undergo self‐renewal, and a multilineage differentiation potential. Cancer stem …

A concise review on cancer treatment methods and delivery systems

E Bidram, Y Esmaeili, H Ranji-Burachaloo… - Journal of Drug Delivery …, 2019 - Elsevier
The ultimate purpose of current cancer research is to develop a comprehensive treatment for
cancer. Recent studies have shown an increased interest in investigating the capacity of …

Characterization of biomarkers of tumorigenic and chemoresistant cancer stem cells in human gastric carcinoma

PH Nguyen, J Giraud, L Chambonnier, P Dubus… - Clinical Cancer …, 2017 - AACR
Purpose: Gastric carcinomas are heterogeneous, and the current therapy remains
essentially based on surgery with conventional chemotherapy and radiotherapy. This study …

Distant metastasis in colorectal cancer patients—do we have new predicting clinicopathological and molecular biomarkers? A comprehensive review

S Filip, V Vymetalkova, J Petera, L Vodickova… - International journal of …, 2020 - mdpi.com
Colorectal cancer (CRC) remains a serious health problem worldwide. Approximately half of
patients will develop distant metastasis after CRC resection, usually with very poor …

Gastric cancer stem cells: evidence, potential markers, and clinical implications

D Brungs, M Aghmesheh, KL Vine, TM Becker… - Journal of …, 2016 - Springer
Gastric cancer is a significant global health problem. It is the fifth most common cancer and
third leading cause of cancer-related death worldwide (Torre et al. in CA Cancer J Clin 65 …

[HTML][HTML] CD133: to be or not to be, is this the real question?

E Irollo, G Pirozzi - American journal of translational research, 2013 - ncbi.nlm.nih.gov
Abstract CD133 (prominin-1) is a member of the transmembrane glycoprotein family and
was initially described as a specific marker to select human hematopoietic progenitor cells …

CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence

K Hirata, H Suzuki, H Imaeda, J Matsuzaki… - British journal of …, 2013 - nature.com
Background: Multiple early gastric cancers (EGCs) may develop in 6–14% of patients even
after achieving curative endoscopic submucosal dissection (ESD); however, a useful …